Loading...
Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
Elotuzumab, targeting signaling lymphocytic activation molecule family 7 (SLAMF7), has been approved in combination with lenalidomide and dexamethasone (ELd) for relapsed/refractory multiple myeloma (MM) based on the findings of the phase III randomized trial ELOQUENT-2 (NCT01239797). Four-year foll...
Na minha lista:
| Udgivet i: | Mediterr J Hematol Infect Dis |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Università Cattolica del Sacro Cuore
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5841936/ https://ncbi.nlm.nih.gov/pubmed/29531651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2018.014 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|